# Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

> **NCT05569655** · NA · UNKNOWN · sponsor: **Chinese Pulmonary Vascular Disease Research Group** · enrollment: 100 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension
- Randomized Controlled Trial

## Interventions

- **DRUG:** Tolvaptan
- **DRUG:** Furosemide

## Key facts

- **NCT ID:** NCT05569655
- **Lead sponsor:** Chinese Pulmonary Vascular Disease Research Group
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-06
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05569655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05569655, "Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05569655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*